Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

540
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

789
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
789
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.4K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.4K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

726
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
726

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.

Journal of comparative effectiveness research·2026
Same author

In Vivo Base Editing of <i>PCSK9</i> with VERVE-102 for Hypercholesterolemia.

The New England journal of medicine·2026
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Interrelationship Between Socioeconomic Status, Depression, and Neuropathy in People with Diabetes: A Cross-Sectional Study.

Journal of clinical medicine·2026
Same author

Prevention and treatment of hypertriglyceridemia-mediated acute pancreatitis: A narrative review.

European journal of internal medicine·2025
Same author

Rare variant genetic landscape of familial chylomicronemia syndrome (FCS) in the United Kingdom.

Genetics in medicine open·2025
Same journal

Right ventricular dysfunction: an overlooked predictor of sudden cardiac death and arrhythmic events-a meta-analysis.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Natural history and outcomes of post-operative atrial fibrillation after non-cardiac surgery: a clinically adjudicated single-center retrospective study.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Risk factors of atrial fibrillation progression in patients with congenital heart disease.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Evaluation of neutrophil oxidative burst capacity in relation to major adverse cardiac events and infection in patients with cardiovascular disease.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Uric acid and subclinical atherosclerosis: distinct associations across coronary and carotid arteries.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Real-world characteristics and management of ventricular tachycardias in ICD patients: Data from the VIDEO registry.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Evidence-based goals in LDL-C reduction.

Handrean Soran1,2, Ricardo Dent3,4, Paul Durrington5

  • 1Cardiovascular Research Group, School of Biomedicine, University of Manchester, Core Technology Facility, Manchester, UK. Handrean.Soran@cmft.nhs.uk.

Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|January 27, 2017
PubMed
Summary
This summary is machine-generated.

Intensive lowering of low-density lipoprotein cholesterol (LDL-C) provides cardiovascular benefits. Greater LDL-C reduction, especially with advanced therapies, offers significant cardiovascular disease risk reduction, particularly for high-risk patients.

Keywords:
EzetimibeLDL cholesterolPCSK9Residual riskStatin

More Related Videos

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

693
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Experiment Videos

Last Updated: Mar 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

693
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Cardiovascular disease (CVD) event reduction with statin therapy correlates with the magnitude of low-density lipoprotein cholesterol (LDL-C) lowering.
  • Epidemiological and genetic studies support a graded, cardio-protective effect of lifelong low atherogenic cholesterol exposure.
  • Current LDL-C treatment targets may not represent a threshold for benefit, suggesting potential advantages for further LDL-C reduction.

Purpose of the Study:

  • To review safety and efficacy data of therapies providing LDL-C lowering beyond statin therapy.
  • To evaluate the implications of intensive LDL-C lowering for current guideline targets.
  • To discuss the role of pre-treatment LDL-C levels and statin therapy in CVD event prevention.

Main Methods:

  • Review of recent safety and efficacy data from clinical trials of adjunctive LDL-C lowering therapies.
  • Analysis of epidemiological and genetic studies on cholesterol exposure and cardiovascular risk.
  • Discussion of current treatment guidelines in the context of pre-treatment LDL-C concentrations.

Main Results:

  • Evidence suggests a continuous relationship between LDL-C reduction and CVD event reduction, without a discernible threshold.
  • The number of patients needing treatment to prevent a CVD event varies significantly based on pre-treatment LDL-C levels.
  • Patients with the highest LDL-C levels, even on maximal statin and ezetimibe therapy, achieve the greatest benefit from PCSK9 inhibitors.

Conclusions:

  • Intensive LDL-C lowering, particularly with advanced therapies like PCSK9 monoclonal antibodies, offers substantial CVD risk reduction.
  • Pre-treatment LDL-C concentration is a critical factor in determining the absolute benefit of LDL-C lowering therapies.
  • Current treatment guidelines may need to consider more aggressive LDL-C lowering strategies for certain patient populations.